Cardiovascular Pharmaceuticals Market ‐Cardiovascular Pharmaceuticals Market IndiaApril 2012
Executive Summary                    Cardiovascular pharmaceuticals market in India is valued at INR X bn in 20‐‐    Mark...
•Introduction   t oduct o•Market Overview                  g•Drivers & Challenges•Government Initiatives•Market Value Chai...
Indian cardiovascular pharma market is expected to witness  huge growth in the coming years Indian Market – Overview      ...
Drivers & Challenges ‐ Summary  Drivers                                                             Challenges  Increasing...
Government Initiatives – Summary                               Reduction in drug prices                                   ...
Public: Domestic Company – A Company (1/3) Company Information                                                         Off...
Public: Domestic Company – A Company (2/3)  Financial Snapshot   i    i lS     h                                          ...
Public: Domestic Company – A Company (3/3) Key Business Segments                                                          ...
Thank you for the attentionThe Cardiovascular Pharmaceuticals  Market – India report is part of Netscribes’ Healthcare Ind...
Upcoming SlideShare
Loading in …5

Market Research Report : Cardiovascular Pharmaceuticals Market in India 2012


Published on

For the complete report, get in touch with us at :

The report begins with the introduction section which offers a brief insight into the major cardiovascular drug classes. It then moves to the market overview section which provides an insight into the global market and then moves on to the Indian market, highlighting the market size and growth.

An analysis of the drivers explains the factors for growth of the industry including increasing patient population, patent expiry of blockbuster drugs, increase in disposable income and introduction of newer and better drugs. The key challenges include strong competition between the different pharma companies and competition from complementary and alternative medicines.

The government initiatives section gives analyses the efforts to reduce drug prices, changes in the customs duty structure and the various control programmes undertaken by the Government.

A brief overview of the drug market value chain, drug regulations and patents is presented in the next section. It analyses the pharmaceutical value chain, and focuses on the different stages of clinical trial that a drug must pass through. Drug regulations in India and drugs approved for marketing have been provided.
A snapshot of different regulatory frameworks existing in the Indian pharma industry has been shown. The section also provides a list of important patent approvals for cardiovascular drugs.

The competition section gives overview of pharmaceutical companies in the country operating in the cardiovascular pharmaceutical industry. The report highlights features of the major players operating in the market in detail. It includes elaborate profile of the major players in the market along with their financial analysis. It also incorporates the recent developments in the Cardiovascular Pharmaceutical industry.

Published in: Business, Health & Medicine
  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Market Research Report : Cardiovascular Pharmaceuticals Market in India 2012

  1. 1. Cardiovascular Pharmaceuticals Market ‐Cardiovascular Pharmaceuticals Market IndiaApril 2012
  2. 2. Executive Summary  Cardiovascular pharmaceuticals market in India is valued at INR X bn in 20‐‐ Market Market  The market is expected to grow at a CAGR of y% from 20‐‐‐‐‐  CVD segment is the second largest contributor to domestic sales, contributing around x %  Drivers: Challenges:  Increasing patient base  Strong competition Drivers and   Patent expiry of blockbuster drugs  Competition from complementary and  Challenges alternative medicines  Increasing disposable income  Introduction of new drugs Introduction of new drugs  Drug value chainDrug regulation   Phases of clinical trial and patents p  Approval and licensing of drugs  Patent approvals  Reduction in drug prices Government   Changes in tax structure initiatives  Control Programmes g  Highly fragmented market with large number of players Major Public Companies Major Private Companies Competition Company 1  Company 4  Company 7  Company 10 Company 1    Company 4 Company 2  Company 5  Company 8  Company 11 Company 2 Company 3  Company 6  Company 9   Company 12 Company 3 CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2012.PPT 2
  3. 3. •Introduction t oduct o•Market Overview g•Drivers & Challenges•Government Initiatives•Market Value Chain, Regulation and  Patents•Competition•Strategic Recommendation•Appendix CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2012.PPT 3
  4. 4. Indian cardiovascular pharma market is expected to witness  huge growth in the coming years Indian Market – Overview  Market Size and Growth • Cardiovascular therapeutic segment belongs to the  INR bn chronic segment (comprising of cardiovascular, anti  150 x6 diabetics and neuro pshychiatry), which together  y% x5 account for around A% of the total pharma market 100 x4 x3 x2 • Cardiovascular segment is the second largest  x 1 50 contributor to domestic  pharmaceuticals market  contributor to domestic pharmaceuticals market sales, with a share of x% 0 2010 2011e 2012e 2013e 2014e 2015e  Within the cardiovascular segment, antihypertensive drugs  account for almost m% of revenue Top Pharmaceutical Segments – 20‐‐  Cholesterol lowering drugs account for one third of sales Cholesterol lowering drugs account for one third of sales 0 2 4 6 8 10 12 14 16 18 • Presently the market has a size of INR X bn and is  anti‐infectives % Y 1 expected to grow at a CAGR of y% from 20‐‐ to 20‐‐ to  CVD Y 2 reach INR Y bn gastro Y 3 CNS Y 4 • Annually, B million Indians die of cardiovascular  respiratory Y 5 diabetes Y 6 diseases pain y 7 gynaecology Y 8 • According to WHO estimates, by 2020, almost a% of  urology y 9 oncology Y 10 cardiac patients worldwide will be Indian cardiac patients worldwide will be IndianSource: CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2012.PPT 4
  5. 5. Drivers & Challenges ‐ Summary Drivers Challenges Increasing patient base Strong competition Patent expiry of blockbuster drugs Competition from complementary and  alternative medicines Increasing disposable income Introduction of new drugs CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2012.PPT 5
  6. 6. Government Initiatives – Summary  Reduction in drug prices  Government Initiatives I iti ti Control programs Control programs Changes in tax structure Changes in tax structure CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2012.PPT 6
  7. 7. Public: Domestic Company – A Company (1/3) Company Information Offices and Centres – India  X Road Corporate Address Bangalore Tel No. Tel No. +91 xx xxxxx xxxxx +91 xx xxxxx xxxxx Fax No. +91 xx xxxxx xxxxx Website Year of Incorporation 19‐‐ Ticker Symbol xxxxxx Stock Exchange NNN Products and Services Products and Services City A   City A Head Office Category Products/Services CVD, CNS, respiratory, dermatology,  Key People Pharmaceutical orthopedics, nutritional, urology, anti‐ infectives i f i Name Designation Infectious diseases, metabolic diseases,  Person M Founder Molecule  inflammatory/respiratory diseases, and  Person N CFO Development oncology Person O Head Person Q PresidentSource: CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2012.PPT 7
  8. 8. Public: Domestic Company – A Company (2/3) Financial Snapshot i i lS h Key Ratios K i Revenue Profit Particulars  y‐o‐y change 20‐‐ 20‐‐ 20‐‐ 20‐‐ INR mn  Revenue INR mn  Profitability Ratios q r Profit / Loss10,000 p Operating Margin s Net Margin n Profit Before Tax Margin 5,000 m n o p 0 Return on Equity t Return on Capital Employed 0 ‐m Return on Working Capital 20‐‐ 20‐‐ 20‐‐ 20‐‐ Return on Assets Financial Summary  Return on Fixed Assets Cost Ratios • The company incurred a net loss of INR xx mn in FY 20‐‐, as  Operating costs (% of Sales) compared to net profit of INR  yy mn in FY 20‐‐ Administration costs (% of  • The company reported total income of  INR xx bn in FY 20‐‐,  Sales) registering an increase of yy per cent over FY 20‐‐ registering an increase of yy per cent over FY 20 Interest costs (% of Sales) Interest costs (% of Sales) Liquidity Ratios • The company earned an operating margin of x per cent in FY 20‐‐ a  Current Ratio decrease of y percentage points over FY 20‐‐ Cash Ratio • The company reported debt to equity ratio of x in FY 20‐‐, an  Leverage Ratios increase of y per cent over FY 20‐‐ Debt to Equity Ratio Debt to Capital Ratio b i l i Financial Summary  Interest Coverage Ratio Indicators Present Value  Efficiency Ratios Market Capitalization (INR) X units Fixed Asset Turnover Total Enterprise Value (INR) Y units Asset Turnover Current Asset Turnover EPS (INR) EPS (INR) Z units Z units Working Capital Turnover PE Ratio (Absolute) A Capital Employed Turnover Source: Improved Decline CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2012.PPT 8
  9. 9. Public: Domestic Company – A Company (3/3) Key Business Segments Key Geographic Segments m n o x y z x x x x x x x y x y y y y y y y z z z z z z z z 20‐‐ 20‐‐ 20‐‐ 20‐‐ 20‐‐ 20‐‐ 20‐‐ 20‐‐ Key Recent Developments Description  i i News • Company A is an integrated research based company that produces a wide range of generic medicines Overview • Serves customers in over 100 countries with manufacturing facilities in several countries Cardiovascular  Cardiovascular • Products include include Product 1 and Product 2  Pharmaceuticals • Is making consistent effort for continual improvement in rural areas with respect to accessibility of  Key Initiatives medicinesSource: CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2012.PPT 9
  10. 10. Thank you for the attentionThe Cardiovascular Pharmaceuticals  Market – India report is part of Netscribes’ Healthcare Industry Series. For more detailed information or customized research requirements please contact:Contact Number: +91 33 4064 6215 C N b 91 33 4064 621E‐Mail: sales@netscribes.comNetscribes (India) Pvt. Ltd. is dedicated to disseminating information and providing quick insights on  hot industries in India and otherNetscribes (India) Pvt Ltd is dedicated to disseminating information and providing quick insights on “hot” industries in India and other emerging markets. Track our new releases and major updates in these industries onAbout NetscribesNetscribes is a knowledge‐consulting and solutions firm with clientele across the globe. The company’s expertise spans areas of investment &  g g f g p y p p fbusiness research, business & corporate intelligence, content‐management services, and knowledge‐software services. At its core lies a true value proposition that draws upon a vast knowledge base. Netscribes is a one‐stop shop designed to fulfil clients’ profitability and growth objectives.Disclaimer: This report is published for general information only. Although high standards have been used the preparation, Netscribes (India) Disclaimer: This report is published for general information only Although high standards have been used the preparation Netscribes (India)Pvt. Ltd. or “Netscribes” is not responsible for any loss or damage arising from use of this document. This document is the sole property of Netscribes (India) Pvt. Ltd. and prior permission is required for guidelines on reproduction. CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2012.PPT 10